MEDROL (methylprednisolone acetate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Approved for dermatomyositis, polymyositis, systemic lupus erythematosus and 4 more indications. First approved in 1977.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
MEDROL (methylprednisolone acetate) is a synthetic glucocorticoid administered as a rectal enema that exerts potent anti-inflammatory and immunomodulatory effects. It is indicated for inflammatory and autoimmune conditions including ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, asthma, atopic dermatitis, and myositis. The drug works by modifying the body's immune response and reducing inflammation across multiple organ systems.
This product is approaching loss of exclusivity with minimal Part D traction, indicating a small, stable team focused on maintenance rather than growth initiatives.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt retaining properties, are used in replacement therapy in adrenocortical deficiency states. Their synthetic…
Worked on MEDROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Depo-Medrol on Psoas After LLIF
A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients
A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients
Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee
A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moThis product offers limited career growth given its LOE-approaching status and minimal Part D utilization ($11K annual spending, 758 claims). Career prospects are constrained to maintenance-focused roles, with primary focus on managed reimbursement, legacy account management, and supporting transition strategies.